title: The effects of resveratrol on cyclooxygenase-1 and cyclooxygenase-2 mRNA and protein levels in diabetic rat kidneys.
abstract: Cyclooxygenase (COX), which have the isoforms of COX-1 and COX-2, is the key enzyme of prostaglandins biosynthesis. Especially, COX-2 is induced in inflammatory disease such as Diabetes Mellitus (DM). Resveratrol (RSV), a natural antioxidant, has a beneficial role in prevention of inflammatory disease. We investigated the changes of COX-1 and COX-2 mRNA expression and protein level in diabetic rat kidney after RSV treatment. Three months-old, 44 Wistar albino male rats, which were divided into six groups such as control group, sodium citrate buffer (sham control) group, diabetic group (DM), Dimethyl Sulfoxide induced control group, RSV treated sham control group (RSV) and RSV treated diabetic group (DM + RSV) were used for the study. Experimental diabetes was induced by intraperitoneal injection of 55 mg/kg Streptozotocin. After the induction of chronic diabetes 10 mg/kg per day RSV was administered intraperitoneally for 4 weeks. In this study. RSV has no significant effect on COX-1 mRNA expression in diabetic rat kidney (P > 0.05). Immunohistochemical study showed that COX-1 expression was slightly inhibited in RSV group and was not significantly supressed in DM + RSV group. When comparing control and treated groups, there were no significant differences in COX-2 mRNA or protein levels (P > 0.05). In conclusion, our results indicate that resveratrol do not significantly affect COX gene and protein expression. Therefore, different therapy strategies such as combination with other antidiabetic drugs may tried in STZ induced animal model for reducing diabetic symptoms and altering COX-1 and COX-2 mRNA or protein levels.
authors.affiliation: Department of Medical Biology and Genetics, Faculty of Medicine, Gazi University, Besevler, 06500 Ankara, Turkey. atiyeseda@yahoo.com
authors.forename: Atiye Seda
authors.initials: AS
authors.lastname: Yar
authors.forename: Sevda
authors.initials: S
authors.lastname: Menevse
authors.forename: Ebru
authors.initials: E
authors.lastname: Alp
authors.forename: Fatma
authors.initials: F
authors.lastname: Helvacioglu
authors.forename: Gulnur
authors.initials: G
authors.lastname: Take
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects; D051545:Cyclooxygenase 1 / Q000235:genetics* / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000235:genetics* / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000201:enzymology* / Q000235:genetics*; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects*; D007150:Immunohistochemistry; D007668:Kidney / Q000187:drug effects / Q000201:enzymology* / Q000473:pathology; D008297:Male; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D000077185:Resveratrol; D012984:Software; D013267:Stilbenes / Q000494:pharmacology*
chemical_list: D012333:RNA, Messenger; D013267:Stilbenes; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D000077185:Resveratrol
references.citation: J Clin Invest. 2001 Apr;107(7):889-98
references.pmid: 11285308
references.citation: Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1339-46
references.pmid: 16434553
references.citation: Pharmacology. 2006;76(2):69-75
references.pmid: 16286809
references.citation: Life Sci. 2000 Jan 14;66(8):663-73
references.pmid: 10680575
references.citation: Biochem Pharmacol. 1998 Mar 15;55(6):811-6
references.pmid: 9586953
references.citation: FASEB J. 1998 Sep;12(12):1063-73
references.pmid: 9737710
references.citation: Drugs Exp Clin Res. 1998;24(1):51-5
references.pmid: 9604148
references.citation: Free Radic Biol Med. 2006 Jul 15;41(2):177-84
references.pmid: 16814095
references.citation: Clin Chim Acta. 1995 Mar 31;235(2):207-19
references.pmid: 7554275
references.citation: N Engl J Med. 1994 Nov 24;331(21):1428-36
references.pmid: 7969282
references.citation: Drugs Exp Clin Res. 2000;26(2):47-55
references.pmid: 10894555
references.citation: Life Sci. 2005 Apr 1;76(20):2299-314
references.pmid: 15748624
references.citation: Science. 1997 Jan 10;275(5297):218-20
references.pmid: 8985016
references.citation: Biochem Pharmacol. 2000 Apr 1;59(7):865-70
references.pmid: 10718345
references.citation: Annu Rev Pharmacol Toxicol. 1998;38:97-120
references.pmid: 9597150
references.citation: Nucleic Acids Res. 2002 May 1;30(9):e36
references.pmid: 11972351
references.citation: Am J Physiol. 1998 Oct;275(4):F613-22
references.pmid: 9755133
references.citation: J Nutr. 2002 Feb;132(2):257-60
references.pmid: 11823587
references.citation: Lancet. 1993 Apr 24;341(8852):1103-4
references.pmid: 8097009
references.citation: Prostaglandins Leukot Essent Fatty Acids. 1997 Feb;56(2):157-63
references.pmid: 9051726
references.citation: Toxicol Sci. 2004 Dec;82(2):614-9
references.pmid: 15329443
references.citation: Mol Med. 2008 Mar-Apr;14(3-4):222-31
references.pmid: 18235842
references.citation: J Biol Chem. 1998 Aug 21;273(34):21875-82
references.pmid: 9705326
references.citation: Annu Rev Biochem. 2000;69:145-82
references.pmid: 10966456
references.citation: J Cardiovasc Pharmacol. 2002 Nov;40(5):762-9
references.pmid: 12409985
references.citation: Mutat Res. 2004 Nov 2;555(1-2):65-80
references.pmid: 15476852
references.citation: J Biol Chem. 2004 May 21;279(21):22727-37
references.pmid: 15020596
references.citation: J Clin Invest. 1994 Dec;94(6):2504-10
references.pmid: 7989609
references.citation: Br J Nurs. 2008 Mar 27-Apr 9;17(6):356-61
references.pmid: 18414303
references.citation: J Biol Chem. 1996 Dec 27;271(52):33157-60
references.pmid: 8969167
references.citation: Nihon Rinsho. 2006 Jan;64(1):112-6
references.pmid: 16408457
references.citation: Diabetes. 2008 Jun;57(6):1446-54
references.pmid: 18511445
references.citation: Cancer Res. 2002 Sep 1;62(17):4945-54
references.pmid: 12208745
references.citation: Pharm Res. 2002 Dec;19(12):1907-14
references.pmid: 12523673
references.citation: FASEB J. 2003 Nov;17(14):1975-85
references.pmid: 14597667
references.citation: Carcinogenesis. 2001 Aug;22(8):1111-7
references.pmid: 11470738